The biomarker CA125, a peptide epitope located in several tandem repeats of the mucin MUC16, is the gold standard for monitoring regression and recurrence of high-grade serous ovarian cancer in response to therapy. The gene discussed is MUC5AC; the disease is ovarian serous adenocarcinoma.